An electrochemical method has been developed for determining NADH in whole blood for dehydrogenasebased assays by flow-injection analysis. NADH generated by dehydrogenase is oxidized by an electron-transfer coupling reagent, 2,6-dichloroindophenol (DCIP). The reduced form of DCIP (DCIPH2) is measured amperometrically by flow-injection analysis. Endogenous interferents were inhibited by p-hydroxymercunbenzoate.
Electrode fouling by proteins was not observed under assay conditions. The EmitTM theophylline enzyme immunoassay and the hexokinase glucose assay were used as models. For the glucose assay, the intraassay CVs were 15% at 0.31 g/L and 3.5% at 1.82 g/L. Recoveries of glucose from whole blood (comparedwith that for aqueous standards) were 109%, 97.9%, and 101% at 0.050, 2.00, and 5.00 g/L glucose, respectively, and 104%, 101%, and 102% for theophylline at concentrations of 5.0 (low), 16 .4 (medium), and 30.2 (high) mg/L, respectively, with correspondingprecisionsof 12%, 9.5%, and 8.8%. Both assays correlated well with results by reference methods. These studies demonstrate that this method can measure NADH in whole blood without prior separation and that it is potentially applicable to other dehydrogenase-based assays in whole blood. Measurements in whole blood pose problems because of spectral interferences from erythrocytes.
Even after the separation of these cells, the assays are prone to interferences by turbid or heavily colored samples, such as severely hemolyzed, lipemic, or ictenc samples (1, 2). Several advantages are associated with measuring substances in whole blood instead of in serum or plasma, including the elimination of the manual separation step of plasma or serum from whole blood, as well as more rapid and convenient analysis. Eliminating the manual separation step reduces the chance of accidental exposure of laboratorians to specimens that may be infectious. An assay in which NADH can be measured in whole blood ' (10) (11) (12) . The oxidation potential for NADH vs Ag/AgC1 is +750 mV. At such a high potential, proteins in the sample also passivate the electrode surface, causing current responses to decrease continuously (11, 13). Among the procedures developed to avoid this problem is use of a chromatographic column to separate proteins from NADH before measurement (10-12).
In an improved amperometric method for the determination of NADH by flow-injection analysis (14), instead of direct electrochemical oxidation of NADH, the redox coupling reagent 2,6-dichloroindophenol (DCIP) was used to oxidize the generated NADH. 4 The DCIP was chemically reduced to DCIPH2, which was detected by oxidation at the detector electrode (15 Whole-blood samples were kept at 4#{176}C after collection. Some whole-blood specimens were kept at 4#{176}C for as long as 2 weeks.
Whole-blood samples for the recovery study and the calibration curve were made by adding aqueous analyte solutions to whole blood in a volume ratio of 1:20 to generate the desired analyte concentrations.
Procedure
The assay procedure for theophylline was similar to that described elsewhere (17) except that, in the first dilution step, the first diluent was either water or HMB solution instead of pH 8.0 Tris buffer. The required sample dilution by the original enzyme immunoassay was 108-fold. The enzymatic product was further diluted 5-or 10-fold into a DCIP solution to stop the enzymatic reaction and to initiate the redox coupling reaction. Hence, the total sample dilution before injection into the sample loop was 540-or 1080-fold.
For the glucose assay, the original enzyme reagent was diluted twofold with water to slow the enzymatic reactions so the assay could be performed manually. Samples were initially diluted 15-fold with water or HMB solution to lyse the red blood cells. The erythrocytes were lysed very rapidly, yielding a homogeneous solution, as confirmed by microscope, within a couple of minutes.
The enzymatic reaction
was initiated by adding 500 L of the enzyme reagent to 50 L of hemolysate or calibrators. The final ratio of reagent to sample was the same as described in the original assay package insert. Sample dilution was 150-fold, as usual, for the enzyme assay plus a further 5-fold dilution into DCIP solution.
We used two-point kinetic methods for both assays, sampling the enzymatic reaction at 30 s and 7 mm.
Two portions (100 L each) of each sampled solution were transferred at these times to two separate portions (400 L) of DCIP solution, and the reaction was allowed to proceed for 7 mm before injection into the flow system. Fig. 1 illustrates the measured signals for the theophylline calibrators.
For each analyte concentration, two corresponding currents are measured at the stated sampling times. The difference between these two currents (called the 6 current response) reflects the amount of NADH generated, and is semilogarithmically proportional to the theophylline con- analyte concentrations in samples. Background current contributions from electroactive species in the sample were static and were subtracted in measuring the 6 current response. The assay procedure and sampling times were chosen so that the overall throughput of assays reached the maximum that was possible by manual operation. Total assay time was 14 miii for the first duplicate, 12 mm for each following duplicate. Unweighted least-squares regression analysis was used to construct the calibration curves and correlate the methods (Ligand Data Calculation, v2.12e; David G. Rhoads Associates, Kennett Square, PA).
Before starting the assay, we cleaned the electrode electrochemically once daily by holding the electrode potential at 1.2 V for 10 s, then at -0.6 V for 30 s, and at +0.6 V for 30 s. This electrochemical cleaning procedure proved effective for our studies.
Safety Considerations
Although once used as an effective oral germicide (18, 19) , HMB is toxic: LDso = 4.96 mg/kg (intraperitoneal in rats) (19) . Special precautions should be taken when handling this chemical. Read the safety information from the manufacturer carefully before handling.
Universal precautions for handling biohazards were exercised in handling the whole-blood specimens. Experiments with the specimens were performed at University Hospital.
Results and Discussion
Electrode Longevity
One of the problems in the application of amperometnc detection to biological fluids is that the electrode is prone to fouling by the adsorption of proteins and oxidized NADH and by electrochemical polymerization of proteins on the electrode surface (5-13).
Even the redox mediator, DCIP, can foul the electrode if it is oxidized at >400 mV, a potential at which oxidation products diunerize on the electrode surface (15) . In the past, we have avoided this problem by chromatographically separating the NADH and proteins (10-12) and by using a redox mediator to oxidize NADH. In this study, we undertook a systematic evaluation of the effects of carrier-phase composition and the electrode potential on fouling during detection of NADH in diluted whole-blood samples. We found that increasing the ionic strength of the carrier phase and adding surfactant protected the electrode surface. A carrier phase containing 0.2 molfL Tris-HC1 and 0.5 mLIL Tween 20 satisfactorily protected the electrode from fouling by proteins. The imprecision (CV) of the measurement of DCIPH2 at 200 mV in diluted whole blood was substantially improved, being 1% for a solution containing whole blood diluted 30-fold in 570 .LmoIJL DCIP even at an injection interval as short as 15 s (data not shown). Electrode potential played a major role in the electrode fouling by proteins. Electrode fouling by proteins started at> +400 mV in a solution of whole blood diluted 300-fold in 0.2 moLfL Tris-HC1 buffer (pH 7.0); this would have a protein concentration of --0.7 g/L, based on an average value for proteins in whole blood of 205 g/L (20). At these potentials, current response dropped continuously with repeated injections of the protein solution. At potentials at or below 400 mV, however, there was no observable signal loss after repeated injections of this solution. The low oxidation potential, combined with the current composition of the carrier phase, eliminated the problem of electrode fouling by proteins. The actual sample dilution was 540-fold or 1080-fold for the theophyllune assay and 750-fold for the glucose assay, and samples were injected every 3 mm for both assays. With these assay conditions, no electrode fouling was observed. 
(29).
That procedure is also based on the detection of NADH in an Emit system, but involves direct oxidation at a stable platinized activated carbon electrode covered by a membrane.
Assay principle.
The Emit theophylline immunoassay is a homogeneous competitive immunoassay in
.Red blood cells which theophylline and enzyme conjugated to theophylline compete for a limited amount of antibody. Binding of the conjugate to the antibody reduces the enzyme activity. Higher analyte concentrations compete more strongly with conjugate, which leads to less conjugate being bound to antibody and, thus, higher total enzyme activity. The enzyme activity is measured by detecting the corresponding reaction it catalyzes. The enzymatic product, NADH, was measured by the mediated amperometric detection scheme. The analyte concentration is semilogarithmically proportional to the signal response.
Calibration curve, linear range, and detection limit. The calibration curve was linear from 2.5 to 80 mg/L of theophylline in whole blood, which includes the therapeutic range of theophylline in serum (10-20 mgfL) (30). The detection limit (blank + 2 SD) under our conditions was 2 mgfL in whole blood-about the same as for the electrochemical Emit assay in serum, -0.8-2.0 mg/L (17) .
Elimination of end ogenous interferences.
Initially we assayed 37 patients' whole-blood samples by using a calibration curve based on calibrators in whole blood, and compared these results with those measured by FPIA in serum. The comparison showed a large x-axis intercept (bias) of 3.60 mgfL in the linear regression equation, and r = 0.844. The poor correlation and the large bias indicated that there might be interferences from samples, not just a concentration difference between serum and whole blood. A closer examination of the source of the interference was made by comparing calibration curves determined in plasma, whole blood, and erythrocytes separated from the same blood specimen (Fig. 2) . The intercepts of the calibration curves increased dramatically in the order plasma < whole blood < erythrocytes.
For increasing red blood cell content at the same theophylline concentration, the 6 current response increased, which in turn yielded a higher apparent theophylline concentration. After a series of studies, we identified the source of the increase in S current response as endogenous cell membrane NADH-dehydrogenases.
These enzymes catalyzed the slow reaction of NADH with DCIP (14, 15) , and generated a higher concentration of DCIPH2 than in the uncatalyzed reaction in serum or plasma. Thus, the larger 8 current response generated in turn yielded falsely high theophylline concentrations when compared with a serum-based calibration curve. The uneven distribution of cell membranes in different aliquots was the apparent cause of the measured concentrations being greatly scattered and led to large variations between replicates.
The catalytic effect of the endogenous NAI)H-dehydrogenases can be eliminated in two ways: by adding an inhibitor of the endogenous enzymes, or by adding a catalyst (such as excess NADH-dehydrogenase) to move the DCIP-NADH reaction to completion before the detection step so that the endogenous enzymes will not interfere.
The added catalytic enzyme may need special reaction conditions, and its concentration must be high enough to ensure completion of the NADH-DCIP reaction in a short time-factors that could be quite costly. Inhibition has the advantage of not increasing the complexity of the system. Enzyme inhibitor can simply be added to the first aqueous dilution (lysing) solution. We found HMB effective, inhibiting selectively the endogenous NADH-dehydrogenases rapidly and completely at low concentrations (31) . Because the glucose-6-phosphate dehydrogenase (from L. mesenteroides) used in the assay does not have cysteine or cystine (32), it is not inhibited by HMB. Fig.   3 illustrates inhibition of the endogenous NADH-dehydrogenases. In the presence of HMB, the S current responses for whole blood and red blood cells decreased substantially, by 25% and 54%, respectively, whereas those for plasma remained the same. The latter demonstrates the absence of an observable inhibition of the . . (Table 1) . These precision data are satisfactory for the desired goal of CV <12.5% for theophylline monitoring (33). We point out that our procedure was totally manual, and that improvement in precision usually accompanies the automation of a procedure (34). The recovery data indicated that the inhibition of the endogenous interferents was complete without interfering with other reactions. Apparent concentrations from 10 consecutive assays appeared evenly scattered around the mean, and no declining tendency was noticed. This provided additional evidence that no electrode fouling from wholeblood samples was observable under assay conditions. The calibration curve for the electrochemical method was constructed from the Syva serum calibrators. For 58 patients' samples, the whole-blood/serum theophylline concentration ratio (slope) was 0.80. For theophyfline concentrations (C) <20 mgfL, CEC = 0.39 + 0.75 Cji.pjj,, mgfL (S1 = 1.21, r = 0.952, n = 54). The bias plot (Fig. 4b) shows that the points out of agreement by ± 2 SD were below the therapeutic range of 10-20 mg/L of theophylline (30). The apparently even distribution of the data points around the mean line suggests that the measurement error was random. The data are plotted in semilog fashion according to the recommendations of Bland and Altman (35) for data with a concentration bias. In monitoring therapeutic concentrations, theophylline is usually expressed as serum concentration.
However, we found the average concentration of theophylline in erythrocytes to be 51% of that in serum. When the measured whole-blood theophylline concentrations are expressed in terms of those in serum, the results may vary with a change of sample hematocrit Although the slopes of the correlation between methods are much closer to unity after the hematocrit correction, the correlation coefficients do not seem improved, which indicates that hematocrit correction for individual samples is not necessary. Using general correction thus avoids the complexity of measuring both hematocrit and theophyffine concentration for a single whole-blood sample.
We examined the small change in correlation coefficients after the hematocrit correction of individual samples. For the 58 samples assayed, the average hematocrit was 38.4% ± 5.8%; with a confidence interval of 95%, sample hematocrit therefore varied from the mean by 11.6% (2 SD). Given that the theophylline concentration in erythrocytes is about half (5 1%) that in serum, the 11.6% difference in hematocrit is equivalent to a 5.8% contribution to the theophylline concentration in whole blood. This 5.8% contribution in concentration is smaller than the method imprecision, and generates the total imprecision of 13%, 11%, and 10% for theophylline at low, medium, and high concentrations, respectively. Thus, without the individual correction of hematocrit, the total imprecision of this manual assay is equivalent to or smaller than the desired imprecision for theophylline determination (33) . Therefore, using a general correction factor of 0.80 of whole blood/serum can adjust the whole-blood theophylline concentration to the serum value at the 95% confidence interval without causing the total measurement imprecision to exceed that required.
Glucose (HK) Assay
Glucose measurement is one of the most commonly performed assays in the clinical laboratory to assess health status and several diseases such as diabetes mellitus.
The main advantage of using glucose as a model compound is that its concentration difference between plasma and whole blood is well investigated (36) , making it convenient to compare this method with other methods in different matrices. Furthermore, well-established enzymatic methods exist for measuring the glucose content of body fluids (37) . The most common procedures for glucose analysis use enzymes as reagents, e.g., GOD and HK, to increase analytical specificity.
The HK method has been proposed as a Reference Method and the GOD/oxygen consumption method correlates best with it (37). In our approach, we used the glucose (HK) assay as the primary assay coupled with DCIP-mediated amperometric determination of NADH. The GOD/oxygen consumption assay was the comparison method. 
Assay precision.
The assay precisions for wholeblood samples with low (0.31 g/L) and high (1.82 g/L) concentrations of glucose were 15% (n = 11) and 3.3% (n = 15), respectively. The high CV at the low concentration was due mainly to the nearness of the glucose concentration to the detection limit. The absolute concentration variation at the low concentration was small (0.048 gfL), approximately equal to the SD of this manual measurement. Improvement could be expected with an automated system (34) .
Recoveries.
The standard addition method was used to compare the measurements of glucose in whole blood and aqueous solution.
Total glucose concentrations were measured immediately after adding glucose to whole-blood samples; average analytical recovery was 103% (Table 2) . From recovery data determined for aqueous calibrators, we conclude that the glucose concentration measured in whole blood reflected the concentration of glucose in the sample.
Comparison of patients' samples.
We analyzed 30 pairs of plasma and whole-blood samples, each pair having been taken from the same person at the same time and assayed at the same time. Results correlated well with those for plasma by a GOD/oxygen rate glucose assay measured on a Beckman CX3 Clinical System (Fig. 5a ). For individual comparisons of plasma and whole-blood samples, the regression both assays correlated well with the GOD/oxygen rate assay over the full assay range. The bias plot from the same data (Fig. 5b) shows that the measured glucose concentration by this method averaged 0.11 g/L less than that by the GOD method. The differences between the two methods were evenly distributed around the mean line within the limits of agreement, except for three points, two of which were near the upper limit of this method.
Effect of sample hematocrit.
To evaluate the possible effect of hematocrit on glucose measurement, we compared the ratio of glucose concentration in whole blood measured by this method with that in plasma obtained by the Beckman CX3 (Fig. 6) . Because the data points are rather evenly distributed (r2 = 0.06, n = 30), we conclude that there is no obvious relationship between the electrochemically measured values and the sample hematocrit for glucose.
In conclusion, the electrochemical assay provides a simple way to monitor the change of NADH concentration in a dehydrogenase-based assay for the mea- Results by this method correlate well with those by established methods. This procedure should be applicable to other enzyme assays or enzyme immunoassays that use dehydrogenases for amplification and for which the substance to be detected is NADH. Whole-blood samples can be used without removal of the red blood cells, samples that cannot currently be analyzed by spectrophotometry or FPIA.
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